March 2025: The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials

Dr. William Horan (Bristol Myers Squibb) joins AJP Audio to discuss a newly approved, novel treatment for schizophrenia spectrum disorder , which has potential impacts for cognition in patients. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin puts the rest of the March issue into context. 00:45 Horan interview 03:15 Novel mechanism of action in the treatment of schizophrenia 05:39 Side effect profiles 07:20 Clinical impacts 08:31 The need for further investigation 09:58 Limitations 11:05 Further research 13:08 Kalin interview 13:21 Horan et al. 17:34 Levenstein et al. 19:00 Fountoulakis et al. 20:57 Couture et al. 23:18 Stern et al. 27:35 McGirr et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

You can listen to March 2025: The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials online on Radio and Podcast. Open the player on this page to stream the available audio.

March 2025: The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials is an episode from American Journal of Psychiatry Audio by American Psychiatric Association Publishing.

This episode is 32:05 long.

This episode was published on Mar 1, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from American Journal of Psychiatry Audio when more episodes are available from the podcast feed.